Drug Profile
Research programme: hydroxysteroid dehydrogenase inhibitors - InnVentis
Alternative Names: short chain dehydrogenase inhibitors - InnVentisLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator InnVentis
- Class Small molecules
- Mechanism of Action Hydroxysteroid dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Inflammation; Metabolic syndrome; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-syndrome in Germany